Payment overview · 2025
General Payments
$186.56
2 reported records · 1 companies
Healthcare provider profile · identity verified
Kerah Williams, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NEW YORK, NY · NPI 1801022751
Verified facts
What the public records show
CMS Open Payments records show Kerah Williams, M.D. received $186.56 in general payments during 2025 across 2 reported records.
Urgo Medical North America, LLC accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $186.56 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $186.56 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $186.56 | 2 | 2025 |
Source payment records
|
|||||
| DRAWTEX HYDROCONDUCTIVE WOUND DRESSING WITH LEVAFIBER 4X4 Normalized: drawtex hydroconductive wound dressing with levafiber 4x4 |
Device | Urgo Medical North America, LLC | $125.19 | 1 | 2025 |
Source payment records
|
|||||
| URGOK2 Normalized: urgok2 |
Device | Urgo Medical North America, LLC | $125.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1084 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 529 | 63 |
| Lisinopril | Lisinopril | 488 | 60 |
| Omeprazole | Omeprazole | 368 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 367 | 44 |
| Losartan Potassium | Losartan Potassium | 331 | 32 |
| Metformin Hcl | Metformin Hcl | 331 | 40 |
| Gabapentin | Gabapentin | 318 | 41 |
| Januvia | Sitagliptin Phosphate | 296 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 276 | 33 |
| Carvedilol | Carvedilol | 276 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 251 | 30 |
| Vascepa | Icosapent Ethyl | 212 | 23 |
| Naproxen | Naproxen | 205 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 26 |
| Meclizine Hcl | Meclizine Hcl | 162 | 18 |
| Levothyroxine Sodium | Levothyroxine Sodium | 149 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 149 | 19 |
| Ibuprofen | Ibuprofen | 142 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 134 | 19 |
| Meloxicam | Meloxicam | 112 | 20 |
| Famotidine | Famotidine | 108 | 12 |
| Enalapril Maleate | Enalapril Maleate | 102 | 11 |
| Alendronate Sodium | Alendronate Sodium | 96 | 13 |
| Ezetimibe | Ezetimibe | 93 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | suppressed |
| Jardiance | Empagliflozin | 75 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 70 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 68 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 64 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | suppressed |
| Furosemide | Furosemide | 59 | suppressed |
| Glipizide Er | Glipizide | 56 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 54 | suppressed |
| Chlorthalidone | Chlorthalidone | 53 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 53 | suppressed |
| Tradjenta | Linagliptin | 51 | suppressed |
| Eliquis | Apixaban | 46 | suppressed |
| Nifedipine Er | Nifedipine | 45 | suppressed |
| Simvastatin | Simvastatin | 45 | suppressed |
| Novolog Flexpen | Insulin Aspart | 44 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Glipizide | Glipizide | 42 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Kerendia | Finerenone | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 22 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 21 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 13 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Fosamprenavir Calcium | Fosamprenavir Calcium | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186.56 · 2 records | Urgo Medical North America, LLC | DRAWTEX HYDROCONDUCTIVE WOUND DRESSING WITH LEVAFIBER 4X4, URGOK2, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error